The head of Johnson & Johnson’s MedTech division is leaving the company. Ashley McEvoy, executive vice president, worldwide chairman of MedTech, on Tuesday announced she is leaving the New Brunswick-based company to pursue other opportunities. She will be succeeded by Tim Schmid, who most recently served as chairman of J&J MedTech Asia Pacific.
McEvoy joined J&J 27 years ago in the Consumer Products Group, where she oversaw classic brands including Tylenol and Zyrtec and grew her career to serve as president of McNeil Consumer Healthcare. McEvoy moved to MedTech in 2009, where she served as worldwide president of Ethicon and then advanced to become company group chairman of Vision and Diabetes Care prior to assuming her current role. McEvoy is presently serving as chair of the AdvaMed board of directors, the leading global trade association and consortium of companies for the medical devices industry, and also serves on the board of trustees for the Children’s Hospital of Philadelphia.
Schmid is no stranger to his new role; he has held a variety of diverse leadership positions in sales, strategic marketing and general management across multiple businesses and geographies, including chief strategic customer officer for Johnson & Johnson MedTech, where he helped lead transformational changes to Johnson & Johnson’s business-to-business relationships with health systems in the U.S.
“I want to thank Ashley for her leadership and 27 years of service at Johnson & Johnson. She has led significant transformation of our MedTech business resulting in improved performance and allowing us to better meet the needs of patients and consumers around the world,” Joaquin Duato, chairman and CEO said. “We are pleased to have the depth of talent at Johnson & Johnson that allows us to transition to Tim, a respected, results-driven and Credo-based leader,” Duato added.
